CClinicalTrials.gg
Not yet recruitingNCT07823985Updated Sep 17, 2026

Preoperative Embolization for Highly Vascular Brain Tumors

An interventional study of Preoperative Endovascular Embolization in Brain Neoplasms, Meningioma and Hemangioblastoma, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Assiut University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Highly vascular brain tumors, including meningiomas, hemangioblastomas, and certain metastases, have a rich blood supply that can lead to substantial blood loss and technical difficulties during surgical removal. Preoperative endovascular embolization is an adjunctive, catheter-based procedure used to block the feeding blood vessels of the tumor before surgery, aiming to reduce intraoperative bleeding and facilitate safer tumor resection.

The primary purpose of this study is to evaluate the technical feasibility, safety, and effectiveness of preoperative endovascular embolization in patients with highly vascular intracranial tumors.

Participants enrolled in this prospective study will undergo:

  1. Pre-procedural neurological and diagnostic cross-sectional imaging (contrast-enhanced MRI or CT angiography).
  2. Diagnostic digital subtraction angiography (DSA) to map tumor-feeding arteries, followed by super-selective catheterization to deliver embolic materials (polyvinyl alcohol particles, Onyx, or microcoils).
  3. Microsurgical tumor resection within 24 to 72 hours following the embolization procedure.

Researchers will assess the degree of tumor devascularization achieved, the volume of intraoperative blood loss, blood transfusion requirements, total surgical duration, extent of tumor resection, and the occurrence of any procedure-related complications.

02

Conditions studied

  • Brain Neoplasms
  • Meningioma
  • Hemangioblastoma
  • Brain Metastases

Keywords

  • Preoperative Embolization
  • Endovascular Embolization
  • Tumor Devascularization
  • Digital Subtraction Angiography
  • Intraoperative Blood Loss
  • Interventional Neuroradiology
  • Microsurgical Resection
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of a hypervascular brain tumor (e.g., meningioma, hemangioblastoma, or hypervascular metastasis) confirmed by contrast-enhanced MRI or CT
  • Scheduled for preoperative endovascular embolization followed by microsurgical resection

Exclusion criteria

Exclusion Criteria:

  • Severe, uncorrected coagulopathy
  • Severe allergy to iodinated contrast media
  • Severe renal insufficiency (estimated glomerular filtration rate [eGFR] \< 30 mL/min/1.73 m²)
  • Absence of safe arterial access
  • Absence of identifiable tumor-feeding vessels suitable for selective microcatheterization
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    Preoperative Embolization and Surgical Resection

    Participants undergo pre-procedural neurological and imaging assessment, followed by diagnostic digital subtraction angiography (DSA) to identify tumor-feeding vessels. Super-selective microcatheterization is performed to deliver embolic agents (polyvinyl alcohol \[PVA\] particles, Onyx, or microcoils) for tumor devascularization. Post-embolization devascularization is evaluated by repeat DSA/CT, followed by microsurgical tumor resection within 24 to 72 hours.

    Procedure: Preoperative Endovascular Embolization

Interventions

  • ProcedurePreoperative Endovascular Embolization

    Diagnostic cerebral digital subtraction angiography (DSA) is performed to identify tumor-feeding arteries and exclude dangerous anastomoses. Super-selective microcatheterization is then conducted to deliver embolic materials (polyvinyl alcohol \[PVA\] particles, Onyx, or microcoils) directly into the tumor vasculature. Tumor devascularization is quantified via post-procedural DSA/CT (\<50%, 50-80%, or \>80%). Following endovascular devascularization, patients undergo microsurgical tumor resection within 24 to 72 hours.

05

What researchers measure

Primary outcomes

  1. Number of Participants Achieving Defined Grades of Tumor Devascularization

    Tumor devascularization is determined by comparing post-embolization digital subtraction angiography (DSA) or CT angiography against baseline diagnostic imaging. Participants are categorized into three predefined grades based on devascularization of tumor vascular blush: poor (\<50%), moderate (50% to 80%), or good/complete (\>80%).

    Time frame: 24 hours post-embolization

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT07823985
Lead sponsor
Assiut University
Responsible party
Sara Bakhet Abd Elrassol Saleh (Resident of Diagnostic and Interventional Radiology, Assiut University) — Principal investigator
First posted
Sep 17, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Sep 17, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion